Ultragenyx Pharmaceutical Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Emil Kakkis
Chief executive officer
US$12.1m
Total compensation
| CEO salary percentage | 6.6% |
| CEO tenure | 14yrs |
| CEO ownership | 3.3% |
| Management average tenure | 8.8yrs |
| Board average tenure | 8yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$607m |
| Sep 30 2023 | n/a | n/a | -US$635m |
| Jun 30 2023 | n/a | n/a | -US$721m |
| Mar 31 2023 | n/a | n/a | -US$719m |
| Dec 31 2022 | US$12m | US$796k | -US$707m |
| Sep 30 2022 | n/a | n/a | -US$678m |
| Jun 30 2022 | n/a | n/a | -US$506m |
| Mar 31 2022 | n/a | n/a | -US$470m |
| Dec 31 2021 | US$10m | US$769k | -US$454m |
| Sep 30 2021 | n/a | n/a | -US$356m |
| Jun 30 2021 | n/a | n/a | -US$351m |
| Mar 31 2021 | n/a | n/a | -US$204m |
| Dec 31 2020 | US$5m | US$759k | -US$187m |
| Sep 30 2020 | n/a | n/a | -US$256m |
| Jun 30 2020 | n/a | n/a | -US$301m |
| Mar 31 2020 | n/a | n/a | -US$425m |
| Dec 31 2019 | US$7m | US$714k | -US$403m |
| Sep 30 2019 | n/a | n/a | -US$397m |
| Jun 30 2019 | n/a | n/a | -US$371m |
| Mar 31 2019 | n/a | n/a | -US$325m |
| Dec 31 2018 | US$5m | US$680k | -US$198m |
| Sep 30 2018 | n/a | n/a | -US$192m |
| Jun 30 2018 | n/a | n/a | -US$183m |
| Mar 31 2018 | n/a | n/a | -US$204m |
| Dec 31 2017 | US$7m | US$638k | -US$302m |
Compensation vs Market: Emil's total compensation ($USD12.14M) is above average for companies of similar size in the UK market ($USD2.62M).
Compensation vs Earnings: Emil's compensation has increased whilst the company is unprofitable.
CEO
Emil Kakkis (63 yo)
14yrs
Tenure
US$12,140,330
Compensation
Dr. Emil D. Kakkis, MD, Ph D., is Venture Advisor of Forge Life Science Partners. He is Founder for Ultragenyx Pharmaceutical Inc. He has been the Chief Executive Officer and President of Ultragenyx Pharma...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 14yrs | US$12.14m | 3.28% $ 119.9m | |
| Chief Quality Operations Officer & Executive VP of Translational Sciences | 8.8yrs | US$3.71m | 0.056% $ 2.1m | |
| Executive VP & Chief Commercial Officer | no data | US$3.75m | 0.028% $ 1.0m | |
| Executive VP of Corporate Strategy & CFO | less than a year | no data | no data | |
| Senior VP | 10.3yrs | no data | 0.021% $ 763.7k | |
| Senior Director of Investor Relations & Corporate Communications | no data | no data | no data | |
| Chief Legal Officer & Executive VP of Corporate Affairs | 7.8yrs | US$2.04m | 0.030% $ 1.1m | |
| Chief Human Resources Officer & Executive VP | 3.6yrs | no data | no data | |
| Chief Business Officer & Executive VP | 12.4yrs | US$2.46m | 0.25% $ 9.3m | |
| Senior Vice President of Business Development & Alliance Management | 6.1yrs | no data | no data | |
| Chief Technical Operations Officer and EVP of Gene Therapy Research & Development | 8.9yrs | US$4.24m | 0.049% $ 1.8m | |
| Senior Vice President of Corporate Strategy & Finance | no data | no data | no data |
8.8yrs
Average Tenure
57.5yo
Average Age
Experienced Management: 0LIF's management team is seasoned and experienced (8.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 14yrs | US$12.14m | 3.28% $ 119.9m | |
| Independent Non-Executive Chairman | 9yrs | US$499.44k | 0.021% $ 781.3k | |
| Independent Director | 10.3yrs | US$478.19k | 0.013% $ 484.2k | |
| Independent Director | 5.2yrs | US$466.44k | 0.013% $ 484.2k | |
| Independent Director | 7yrs | US$462.19k | 0.019% $ 698.6k | |
| Independent Director | 2.8yrs | US$465.81k | 0.0046% $ 168.3k | |
| Independent Director | 9.2yrs | US$481.31k | 0.021% $ 781.3k | |
| Independent Director | 2yrs | US$1.24m | 0.0060% $ 220.3k |
8.0yrs
Average Tenure
62yo
Average Age
Experienced Board: 0LIF's board of directors are considered experienced (8 years average tenure).